Most interestingly, the highest numbers of Dsg3-specific memory B cells were observed in 3 PV patients ~2 years after treatment with Rituximab (22–27 months; patient 4, 8, and 13; Supplementary Table 1), while increasing Dsg3-specific memory B cells could not be observed in a PV patient (patient 6) who experienced a relapse 35 months after rituximab (Supplementary Figure 4). Here, DSG3 is linked to acquired polycythemia vera.